X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye. It is being evaluated for the treatment of Dry Eye Disease.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, which is being evaluated for the treatment of neuropathic corneal pain.
Lead Product(s): OK-101
Therapeutic Area: Neurology Product Name: OK-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye. It is being evaluated in phase 2 clinical trials for the treatment of Dry Eye Disease.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
OK-101 is a ChemR23 GPCR agonist, peptide drug candidate, which is currently under clinical development for the treatment of patients suffering from Dry eye disease.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
OKYO intends to use the net proceeds primarily for clinical development of the Company’s product candidates including, OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, to treat ocular diseases.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.8 million Upfront Cash: $5.8 million
Deal Type: Public Offering October 31, 2023
Details:
OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response to treat Neuropathic Corneal Pain.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is developed using a membrane-anchored-peptide (MAP) technology and shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 15, 2023
Details:
OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Freedom Capital Markets
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
Details:
OKYO intends to use the net proceeds from the Offering primarily for clinical development of the Company’s product candidates, including OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.
Lead Product(s): OK-101
Therapeutic Area: Ophthalmology Product Name: OK-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Freedom Capital Markets
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
